Adia Nutrition, Inc. Reports Strong Revenue Growth in 2025 Annual Report, Highlighting Transition to Regenerative Medicine and Full SEC Reporting Status

Rhea-AI Summary

Adia Nutrition (OTCQB: ADIA) reported fiscal 2025 results and a strategic shift into regenerative medicine. Revenue rose to $700,508 from $6,380 in 2024, with gross profit of $191,670. The company recorded an operating loss of $366,492 and net loss of $395,464 and disclosed going-concern doubt.

Adia achieved full SEC reporting status in February 2026 and operates divisions Adia Med, Adia Labs, and Biolete while investing in R&D, clinical services, and infrastructure.

Positive

• Revenue $700,508 in 2025 vs $6,380 in 2024
• Gross profit $191,670 reported for 2025
• Full SEC reporting status effective February 2026
• Revenue mix: ~63% biologics, ~35% medical procedures

Negative

• Operating loss of $366,492 in 2025
• Net loss of $395,464 in 2025
• Disclosure of substantial doubt about going concern
• Projected annual operating costs of $450,000–$750,000 and reliance on financing

Winter Park, Florida--(Newsfile Corp. - April 1, 2026) - Adia Nutrition, Inc. (OTCQB: ADIA), a leader in regenerative medicine, stem cell therapies, and premium wellness solutions, today announced key highlights from its Form 10-K annual report for the year ended December 31, 2025. The filing marks a pivotal year of operational expansion following the company's successful transition from a dormant shell to an active player in the high-growth regenerative healthcare sector.

In 2025, Adia Nutrition achieved total revenue of approximately $700,508, representing a substantial increase from just $6,380 in 2024. This growth was driven primarily by sales of biologic products (approximately 63%) and medical procedures (approximately 35%) through its Adia Labs and Adia Med divisions, with a reduced reliance on supplement sales. Gross profit reached $191,670, while the company reported an operating loss of $366,492 and a net loss of $395,464. Management attributes the improved top-line performance to the launch of clinical services, increased biologics sales, and initial R&D and clinical activities.

"Our 2025 results reflect the successful execution of our strategy to build a scalable platform in regenerative medicine," said Larry Powalisz, Chief Executive Officer of Adia Nutrition. "Revenue grew over 100-fold as we shifted focus toward high-potential stem cell and biologic offerings. With our recent achievement of full SEC reporting status, we are now positioned for greater transparency, investor confidence, and accelerated growth toward potential uplisting."

Key Business and Operational Highlights from the 10-K and Recent Developments:

• Regenerative Medicine Focus: Through Adia Med, the company offers specialized treatments including stem cell therapies for orthopedic conditions, pain management, and wound repair. Adia Med also supports autologous hematopoietic stem cell transplantation (AHSCT) for approved indications such as multiple sclerosis, alongside platelet-rich plasma (PRP) therapies. Adia Labs procures and sells premium biologic products like AdiaVita (umbilical cord blood derived stem cells and exosomes) and AdiaLink (amniotic fluid-derived exosomes), both processed under strict FDA Section 361 and AATB standards.

• Diversified Segments: The company operates through Adia Med (clinical services), Adia Labs (biologics sales), and Biolete (nutritional supplements, including protein coffee with mushroom extracts). It also holds an equity stake in aligned nutrition businesses.

• Full SEC Reporting Milestone: In February 2026, Adia's Form 10 registration statement became effective, making the company a fully reporting entity under the Securities Exchange Act of 1934. This enables regular audited disclosures via 10-K, 10-Q, and 8-K filings, aligning with standards for major exchanges and supporting potential future NASDAQ uplisting efforts.

• Operational Infrastructure: The company maintains a clinic and operations in Winter Park, Florida, with a small but focused team supplemented by medical experts on the board, including physicians specializing in regenerative therapies.

• Market Opportunity: Adia is capitalizing on the expanding stem cell therapy market, projected to reach significant growth in the coming years, by emphasizing minimally manipulated, FDA-registered allogeneic and autologous products.

The company noted ongoing investments in clinical protocols, staffing, equipment, and R&D, which contributed to higher operating expenses in 2025. Management expects annual operating costs in the range of $450,000-$750,000 and anticipates continued revenue momentum while exploring additional capital sources as needed. Substantial doubt about going concern was disclosed due to historical losses and reliance on financing, consistent with early-stage growth companies in the sector.

Adia Nutrition remains committed to innovation in personalized healthcare, bridging gaps in traditional systems with compassionate, science-backed regenerative solutions.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290856

FAQ

What were Adia Nutrition (ADIA) full-year 2025 revenues and profit figures?

Adia reported $700,508 in revenue for 2025, with a $191,670 gross profit. According to the company, operating loss was $366,492 and net loss $395,464 for the year.

When did Adia Nutrition (ADIA) become a fully reporting SEC company and what does that mean?

Adia became a fully reporting company in February 2026. According to the company, this enables regular audited 10-K, 10-Q, and 8-K disclosures and supports potential future NASDAQ uplisting efforts.

How did Adia Nutrition (ADIA) achieve its 2025 revenue growth and segment mix?

Revenue growth was driven by biologics and clinical services, with approximately 63% from biologic products and 35% from medical procedures. According to the company, sales from Adia Labs and Adia Med powered the increase.

What risks did Adia Nutrition (ADIA) disclose in its 2025 Form 10-K?

The company disclosed substantial doubt about going concern due to historical losses and financing reliance. According to the company, ongoing capital needs and early-stage operating losses present material risk to operations.

What are Adia Nutrition's (ADIA) expected operating costs and cash needs for 2026?

Management expects annual operating costs of $450,000–$750,000 in the near term. According to the company, it will continue investing in R&D, staffing, and clinical protocols while exploring additional capital sources.

How might Adia Nutrition's (ADIA) SEC reporting status affect investors and potential uplisting?

SEC reporting may increase transparency and investor confidence, aligning filings with major-exchange standards. According to the company, this status supports potential future NASDAQ uplisting efforts, subject to meeting exchange requirements.